Combo lymphoma treatment wins FDA approval
The U.S. Food and Drug Administration granted earlier-than-expected approval to Roche Holding AG’s antibody-drug conjugate Polivy for the treatment of patients with advanced lymphoma.
AstraZeneca-Daiichi breast cancer treatment shows promise in latest study
An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan’s Daiichi Sankyo’s met the main goal in a mid-stage study, bolstering the companies’ position in a highly competitive oncology market.
AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal
AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.
Five-Member GO Therapeutics Inks Deal with Roche
GO Therapeutics, with headquarters in Cambridge, Mass., signed a licensing deal with Swiss-based Roche to develop antibodies for cancer.
Celgene Revamps Pact With Sutro Biopharma
Sutro Biopharma and Celgene modified their 2014 immuno-oncology collaboration revolving around four programs that are in preclinical development.
Pfizer’s Besponsa Approved in EU
The European Commission approved Besponsa as monotherapy for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
Immunomedics, Seattle Genetics ink $2 billion deal
Drug developer Immunomedics Inc. entered into a development and licensing deal worth up to $2 billion for its experimental cancer drug with Seattle Genetics Inc.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!